These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 25392319)

  • 1. Prognostic biomarkers of IFNb therapy in multiple sclerosis patients.
    Baranzini SE; Madireddy LR; Cromer A; D'Antonio M; Lehr L; Beelke M; Farmer P; Battaglini M; Caillier SJ; Stromillo ML; De Stefano N; Monnet E; Cree BA
    Mult Scler; 2015 Jun; 21(7):894-904. PubMed ID: 25392319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis.
    Prosperini L; Gallo V; Petsas N; Borriello G; Pozzilli C
    Eur J Neurol; 2009 Nov; 16(11):1202-9. PubMed ID: 19538207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain atrophy as a non-response predictor to interferon-beta in relapsing-remitting multiple sclerosis.
    Rojas JI; Patrucco L; Miguez J; Besada C; Cristiano E
    Neurol Res; 2014 Jul; 36(7):615-8. PubMed ID: 24620963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
    Prosperini L; Borriello G; De Giglio L; Leonardi L; Barletta V; Pozzilli C
    BMC Neurol; 2011 Feb; 11():26. PubMed ID: 21352517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study.
    Prosperini L; Mancinelli CR; Pozzilli C; Grasso MG; Clemenzi A; Collorone S; Pontecorvo S; Francia A; Villani V; Koudriavtseva T; Buttari F; Centonze D; Di Battista G; Frisullo G; Galgani S; Gasperini C
    Eur Neurol; 2014; 71(5-6):233-41. PubMed ID: 24480868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early predictors of non-response to interferon in multiple sclerosis.
    Horakova D; Kalincik T; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
    Acta Neurol Scand; 2012 Dec; 126(6):390-7. PubMed ID: 22428845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between MRI lesion activity and response to IFN-beta in relapsing-remitting multiple sclerosis patients.
    Río J; Rovira A; Tintoré M; Huerga E; Nos C; Tellez N; Tur C; Comabella M; Montalban X
    Mult Scler; 2008 May; 14(4):479-84. PubMed ID: 18562504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
    Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
    Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics of responders to interferon therapy for relapsing MS.
    Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C
    Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis.
    Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
    Eur Neurol; 2008; 59(3-4):131-5. PubMed ID: 18057899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-phospholipid antibodies are associated with response to interferon-beta1a treatment in MS: results from a 3-year longitudinal study.
    Zivadinov R; Ramanathan M; Ambrus J; Hussein S; Ramasamy DP; Dwyer MG; Bergsland N; Minagar A; Weinstock-Guttman B
    Neurol Res; 2012 Oct; 34(8):761-9. PubMed ID: 22971466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Scoring treatment response in patients with relapsing multiple sclerosis.
    Sormani MP; Rio J; Tintorè M; Signori A; Li D; Cornelisse P; Stubinski B; Stromillo Ml; Montalban X; De Stefano N
    Mult Scler; 2013 Apr; 19(5):605-12. PubMed ID: 23012253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
    Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
    Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glypican 5 is an interferon-beta response gene: a replication study.
    Cénit MD; Blanco-Kelly F; de las Heras V; Bartolomé M; de la Concha EG; Urcelay E; Arroyo R; Martínez A
    Mult Scler; 2009 Aug; 15(8):913-7. PubMed ID: 19556317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-beta increases systemic BAFF levels in multiple sclerosis without increasing autoantibody production.
    Hedegaard CJ; Sellebjerg F; Krakauer M; Hesse D; Bendtzen K; Nielsen CH
    Mult Scler; 2011 May; 17(5):567-77. PubMed ID: 21177756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measures in the first year of therapy predict the response to interferon beta in MS.
    Río J; Castilló J; Rovira A; Tintoré M; Sastre-Garriga J; Horga A; Nos C; Comabella M; Aymerich X; Montalbán X
    Mult Scler; 2009 Jul; 15(7):848-53. PubMed ID: 19542263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group.
    Neurology; 1993 Apr; 43(4):655-61. PubMed ID: 8469318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.